The PhD research of our co-founder, Morena Francesca Fiordalisi, was published in Biomaterials Advances. The study investigates how the age of the donor tissue used to derive extracellular matrix (ECM) biomaterials influences intervertebral disc regeneration.
The research demonstrates that ECM materials derived from younger, and particularly fetal, sources create a more supportive biological environment for disc cells. This environment enhances the cells’ ability to restore key structural components required for healthy intervertebral disc function. In addition, the study shows that fetal-derived matrices can reduce abnormal blood vessel formation, a process closely associated with disc degeneration and chronic low back pain.
Peer-reviewed studies are a key component in validating the scientific rationale behind emerging technologies and reducing early-stage technical risk. By anchoring its development in published research, Fetalix demonstrates the depth of expertise within its founding team and the robustness of its approach to intervertebral disc regeneration.
This milestone reinforces the company’s positioning as a science-driven venture and supports the continued translation of its technology toward preclinical validation and future clinical application.
December 1, 2022
